

LCLT1 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP5723b**Specification**

LCLT1 Antibody (C-term) Blocking peptide - Product Information

Primary Accession [Q6UWP7](#)
Other Accession [NP_872357.2](#)

LCLT1 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 253558

Other Names

Lysocardiolipin acyltransferase 1, 231-, 1-acylglycerol-3-phosphate O-acyltransferase 8, 1-AGP acyltransferase 8, 1-AGPAT 8, Acyl-CoA:lysocardiolipin acyltransferase 1, LCLAT1, AGPAT8, ALCAT1, LYCAT

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LCLT1 Antibody (C-term) Blocking peptide - Protein Information

Name LCLAT1

Synonyms AGPAT8 {ECO:0000303|PubMed:16620771}, AL

Function

Exhibits acyl-CoA:lysocardiolipin acyltransferase (ALCAT) activity; catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling (By similarity). Recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors (By similarity). Also exhibits 1-acyl-sn-glycerol-3-phosphate acyltransferase activity (AGPAT) activity; converts 1-acyl-sn-glycerol- 3- phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn- glycerol-3- phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone (PubMed:16620771). Possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities (PubMed:19075029). Required for establishment of the hematopoietic and endothelial lineages (By similarity).

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein

Tissue Location

Expressed at higher level in heart, kidney and pancreas than in brain, spleen, liver, lung, small intestine and placenta.

LCLT1 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

LCLT1 Antibody (C-term) Blocking peptide - Images**LCLT1 Antibody (C-term) Blocking peptide - Background**

Acyl-CoA:lysocardiolipin acyltransferase. Possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities. Recognizes both monolysocardiolipin and dilyocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors. Acts as a remodeling enzyme for cardiolipin, a major membrane polyglycerophospholipid. Converts lysophosphatidic acid (LPA) into phosphatidic acid (PA) with a relatively low activity. Required for establishment of the hematopoietic and endothelial lineages.

LCLT1 Antibody (C-term) Blocking peptide - References

Zhao, Y., et al. J. Lipid Res. 50(5):945-956(2009)Wang, C., et al. Blood
110(10):3601-3609(2007)Agarwal, A.K., et al. Arch. Biochem. Biophys. 449 (1-2), 64-76 (2006)